Grande estudo observacional sugere que antipsicóticos injetáveis de ação longa estão associados a desfechos melhores do que antipsicóticos orais em pessoas com esquizofrenia.
1 Ago, 2022 | 15:12hComentário convidado: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open
Conteúdos relacionados:
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link para o resumo – $ para o texto completo)
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Comentário no Twitter
This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022